Unflame

Gut-skin axis · Pattern story 06

The gut-skin axis is real. 'Your skin disease starts in your gut' is not what it shows.

Picture two city departments linked by a fibre-optic cable. Signals travel between them; that is proven. But when the grass in the park turns brown, blaming the water plant because the cable exists, and selling a bucket of water-plant minerals as the cure, skips the soil, the rainfall and the plant disease. That is roughly where the gut-skin story stands.

By Laxmanna · Updated 2026-10-21 · 7 min read · 16 sources

−3.9

points on the SCORAD eczema scale with probiotics across 39 trials (2,599 people). The smallest change people notice is about 8.7.[14]

66.7% vs 41.9%

PASI-75 response with a specific 3-strain probiotic mixture added to topical steroids in one psoriasis trial. A 6-month single-strain trial found nothing.[11]

60% vs 19%

treatment failure with faecal transplant versus sham in a psoriatic arthritis trial. 'Reset the gut' can go the wrong way.[15]

What the term actually names

'Gut-skin axis' is a legitimate scientific term. It describes two-way communication between the gastrointestinal tract and the skin through measurable channels: microbial metabolites such as short-chain fatty acids and tryptophan-derived indoles, bacterial components such as lipopolysaccharide, the integrity of the intestinal barrier, and immune cells that circulate between the two.[1][4] The signals are real and they can be measured in blood.

What the term does not name is a single disease mechanism. The two skin conditions most often attached to it are biologically different: atopic dermatitis (eczema) is a disease of epidermal barrier disruption and type-2 inflammation (IL-4, IL-13), while psoriasis runs on the IL-23/Th17 axis and keratinocyte over-proliferation.[1][4] A communication route that touches both does not make either one 'a gut disease'.

There is no single gut fingerprint

If skin disease started in the gut, you would expect a recognisable gut signature. The human data do not show one. In infants, early-life differences in gut microbes are associated with later atopic risk during immune development.[9][10] But that is infancy. A systematic review of adults with eczema found no consistent loss of overall gut diversity compared with healthy controls.[5] In psoriasis, cohorts contradict each other: some report lower species richness, others normal diversity with altered composition, and several find higher levels of the so-called beneficial butyrate producer Faecalibacterium prausnitzii in patients than in controls.[6][7][8]

'Leaky gut' fares similarly. Blood markers related to intestinal barrier function (I-FABP, Reg3A, LBP) do correlate with eczema severity in cross-sectional studies, but they are non-specific and cannot tell you which direction the arrow points.[1][12] And almost all of this profiling is done after the skin disease exists, so it cannot show that the gut came first.[4][5]

Differences at the group level, varying by age, diet, geography and medication, are not a diagnostic. No consumer stool test can tell you that your flare is 'gut-caused' or which probiotic to buy.[7][8]

A pathway is not a causal chain

Where the mechanism work is strongest is in mice and cell cultures. Oral butyrate fuels keratinocyte energy metabolism and speeds barrier-protein synthesis in mice.[2] Gut-derived indoles can be converted by the host into indoxyl sulfate, which amplified Th17 skin inflammation in a psoriasis mouse model.[3] In humans, the evidence stops at correlations between blood or stool measures and disease severity, plus cell-culture assays; no one has manipulated the full chain in patients.[1][4]

The same molecule can also push in opposite directions. Some indoles dampen eczema-type inflammation through the aryl hydrocarbon receptor, while their metabolite indoxyl sulfate worsens psoriasis-type inflammation.[3][13] 'Gut metabolites are protective' is not a safe generalisation.

What the intervention trials show

The decisive test is to change the gut and watch the skin. The results are modest and product-specific.

TrialProduct and settingResult
Cochrane review, eczema[14]39 RCTs, 2,599 people, assorted oral probioticsNo significant benefit for patient-rated symptoms; SCORAD −3.91 points, below the ~8.7-point minimal noticeable difference
Navarro-López 2019, psoriasis[11]Specific 3-strain mixture for 12 weeks, added to topical steroidsPASI-75 in 66.7% vs 41.9% on placebo (adjunct, not standalone)
Suriano 2023, psoriasis[16]Single L. rhamnosus strain for 6 months, added to standard care, 103 adultsNo significant difference in PASI or quality of life
FMT trial, psoriatic arthritis[15]Faecal microbiota transplant vs shamTreatment failure 60.0% vs 18.8%, worse with FMT

Two readings follow. A positive adjunct trial shows that one specific formulation gave some extra relief on top of standard treatment; it does not show that the disease began in the gut, and it does not transfer to a different product off a shelf.[7][11] And a null trial, or a harmful one, shows that 'improving the gut' is not a general-purpose lever.[15][16]

What this means for you

  • The gut and skin talk to each other. That is interesting biology and an active research area. It is not evidence that your eczema or psoriasis was caused by a damaged gut.
  • Group-level microbiome differences are inconsistent across studies. There is no stool signature that diagnoses inflammatory skin disease.
  • Probiotics in trials are specific strains tested as additions to prescribed treatment. Results range from modest benefit to none, and they do not generalise across products.
  • Prescribed skin treatments act directly on the immune and barrier problem. Framing them as 'masking a root cause in the gut' is not supported and can lead people to abandon care that works.
  • If gut symptoms and skin symptoms seem to move together in your log, that is a pattern worth describing to your doctor. It is not a diagnosis of a gut cause.

Questions for your doctor

  1. I have both gut and skin symptoms. Is there any reason to think they are connected in my case, or are they two separate conditions?
  2. Is there anything about my gut symptoms (duration, bleeding, weight change) that needs its own evaluation?
  3. Is there any probiotic trial evidence relevant to my specific condition, and would it be as an addition to my current treatment?
  4. I have been offered a stool microbiome test. What, if anything, would you do differently based on the result?
  5. What would make you suspect inflammatory bowel disease or coeliac disease rather than a functional gut problem?

When to seek care

Skin: rapidly spreading redness, severe pain, yellow crusting or weeping; redness over most of the body with chills or fever; sudden painful blisters within eczema with high fever (possible eczema herpeticum, an emergency); widespread pustules with fever. Gut: blood in the stool or black stools, unexplained weight loss or anaemia, severe or night-time abdominal pain, diarrhoea lasting more than four weeks, or gut symptoms with joint pain or eye inflammation. These need prompt medical evaluation.

Things people hear, and what the evidence says

"Eczema and psoriasis start in the gut."
Most human profiling is done after skin disease is established, infant associations do not prove adult causation, and the mechanistic chain is complete only in animal models.[4][5][9]
"Everyone with eczema or psoriasis has gut dysbiosis."
Adults with eczema show no consistent diversity deficit; psoriasis cohorts report lower, higher or unchanged richness.[5][6][7]
"A probiotic will fix your gut and cure your skin."
Across 39 eczema trials the pooled benefit was below the smallest noticeable change. Psoriasis trials range from a modest adjunct effect to null. No product cures either condition.[14][11][16]
"Faecal transplant resets the gut and clears psoriasis."
In the only randomised trial in psoriatic arthritis, treatment failure was higher with FMT than with sham.[15]
"Your skin medication only masks the root cause."
Standard treatments act directly on the immune and barrier dysfunction that is the disease. Stopping them for an unproven gut regimen is a risk, not a cure.

Sources

Primary human studies are marked "primary"; reviews, guidelines and models are labelled. Where a source is an abstract only, that is stated.

  1. Gut dysbiosis and the molecular landscape of the gut-skin axis: comparative mechanistic review. PMC 2025 — review. https://pmc.ncbi.nlm.nih.gov/articles/PMC13072162/
  2. Trompette A et al. Gut-derived short-chain fatty acids modulate skin barrier integrity (mouse plus human cell culture). Mucosal Immunol 2022 — primary. https://pure.manchester.ac.uk/ws/portalfiles/portal/223161069/Trompette_MucImm_2022.pdf
  3. Gut microbe-derived metabolites drive psoriatic inflammation via indoxyl sulfate (mouse mechanism plus human severity correlation). 2025 — primary. https://pubmed.ncbi.nlm.nih.gov/40930076/
  4. The emerging role of gut microbiota in inflammatory skin diseases: systematic review. PMC 2025 — review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12967704/
  5. Gut dysbiosis and adult atopic dermatitis: systematic review. PMC 2024 — review. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721037/
  6. Characterization of the gut microbiota in patients with psoriasis: systematic observational review. PMC 2025 — review. https://pmc.ncbi.nlm.nih.gov/articles/PMC12029981/
  7. Xiao S et al. Deciphering gut microbiota dysbiosis and genetic and metabolic dysfunction in psoriasis: shotgun metagenomic case-control. Front Cell Infect Microbiol 2021 — primary. https://doi.org/10.3389/fcimb.2021.605825
  8. Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients. Sci Rep 2020 — primary. https://doi.org/10.1038/s41598-020-69537-3
  9. Imbalance of gut Streptococcus, Clostridium and Akkermansia in infants who develop atopic dermatitis: prospective infant study. Allergy Asthma Immunol Res 2020 — primary. https://doi.org/10.4168/aair.2020.12.2.322
  10. Gut microbiota composition and development of atopic manifestations in infancy: prospective cohort. PMC 2007 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC1942165/
  11. Navarro-López V et al. Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: randomised controlled trial. Acta Derm Venereol 2019 — primary. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3305
  12. Severity of atopic dermatitis is associated with gut-derived barrier biomarkers: cross-sectional study. PMC 2025 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC12274536/
  13. Bifidobacterium longum-mediated tryptophan metabolism improves atopic dermatitis via the gut-skin axis (human trial plus mouse/culture). Gut Microbes 2022 — primary. https://www.tandfonline.com/doi/full/10.1080/19490976.2022.2044723
  14. Makrgeorgou A et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2018 — systematic review of 39 RCTs. https://www.cochrane.org/evidence/CD006135_probiotics-treating-eczema
  15. Kragsnaes MS et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: randomised sham-controlled trial. Ann Rheum Dis 2021 — primary. https://pubmed.ncbi.nlm.nih.gov/33926922/
  16. Suriano F et al. Efficacy of an adjuvant Lactobacillus rhamnosus formula in improving skin lesions in plaque psoriasis: 6-month randomised trial. 2023 — abstract. https://pubmed.ncbi.nlm.nih.gov/36757438/

Written by Laxmanna · Research-led health writer. Every explainer on Unflame starts from a structured evidence dossier: primary studies retrieved, claims tabulated, contradictions logged, and wording checked against what the sources can support. How the dossiers are built.

Related

Psoriasis

Why psoriasis comes back in the same spot

Cleared psoriasis plaques leave an invisible footprint of resident immune cells and altered genes.

Read the explainer Eczema

Does bad air make eczema flare? What the AQI can and cannot tell you

On high-pollution days, eczema clinic visits rise slightly across millions of records.

Read the explainer